Kedrion stronger in North America and further committed to rare diseases
Agreement with Canadian-based Liminal BioSciences signed on June 22nd
Kedrion Biopharma supports the launch of “Nature Italy”
The Company reaffirms and strengthens its commitment to research and innovation
Kedrion alongside AICE on the 50th Ann. of the first AICE Triennial Conference
The company supports the reading of a scientific study on the role of Factor VIII in the protection of the joints
Kedrion announces the appointment of a new CEO
Val Romberg from the USA, one of the most esteemed managers in the industry
KEDPLASMA GmbH changes its name to Kedrion Biopharma GmbH
Further step towards an even stronger focus on patients in Europe
Kedrion-Kamada collaboration, first patient enrolled in the clinical trial
Yet another milestone in the global Kedrion-Kamada collaboration for the development, manufacturing and distribution of a plasma-derived immunoglobulin (IgG) product as a potential treatment for coronavirus disease (COVID-19). On Aug. 10, 2020 Kamada Ltd. announced that the first patient has been recruited to the Phase 1/2 clinical trial of its anti-SARS-CoV-2 plasma-derived immunoglobulin (IgG) product
Kedrion’s Mother and Child Health campaign for Asia and MEA announced
Details were unveiled during our first televised Regional Distributor Meeting on July 14th-15th
COVID-19. Kedrion partners with Columbia University Irving MC
Kedrion and Columbia University release video statements
Kedrion-Kamada collaboration, first batch of Covid-19 IG released in Israel
The two companies are now working to expand the Clinical Development Program to the US